Renalytix Plc RENX.L Stock
Renalytix Plc Price Chart
Renalytix Plc RENX.L Financial and Trading Overview
| Renalytix Plc stock price | 32.5 GBP |
| Previous Close | 82.5 GBP |
| Open | 82.9 GBP |
| Bid | 80 GBP x 0 |
| Ask | 85 GBP x 0 |
| Day's Range | 82.9 - 82.98 GBP |
| 52 Week Range | 44 - 174.78 GBP |
| Volume | 10.76K GBP |
| Avg. Volume | 62.77K GBP |
| Market Cap | 77.82M GBP |
| Beta (5Y Monthly) | 1.9585 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.36 GBP |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.67 GBP |
RENX.L Valuation Measures
| Enterprise Value | 55.97M GBP |
| Trailing P/E | N/A |
| Forward P/E | -2.1276925 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 20.941845 |
| Price/Book (mrq) | 429.94818 |
| Enterprise Value/Revenue | 15.061 |
| Enterprise Value/EBITDA | -1.244 |
Trading Information
Renalytix Plc Stock Price History
| Beta (5Y Monthly) | 1.9585 |
| 52-Week Change | -46.77% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 174.78 GBP |
| 52 Week Low | 44 GBP |
| 50-Day Moving Average | 88.35 GBP |
| 200-Day Moving Average | 86.48 GBP |
RENX.L Share Statistics
| Avg. Volume (3 month) | 62.77K GBP |
| Avg. Daily Volume (10-Days) | 44.77K GBP |
| Shares Outstanding | 93.78M |
| Float | 69.66M |
| Short Ratio | N/A |
| % Held by Insiders | 43.77% |
| % Held by Institutions | 9.92% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | June 30, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -1219.26% |
| Gross Margin | 27.28% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -67.20% |
| Return on Equity (ttm) | -166.93% |
Income Statement
| Revenue (ttm) | 3.72M GBP |
| Revenue Per Share (ttm) | 0.05 GBP |
| Quarterly Revenue Growth (yoy) | -10.80% |
| Gross Profit (ttm) | 874K GBP |
| EBITDA | -44985000 GBP |
| Net Income Avi to Common (ttm) | -39656000 GBP |
| Diluted EPS (ttm) | -0.58 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 33.03M GBP |
| Total Cash Per Share (mrq) | 0.35 GBP |
| Total Debt (mrq) | 11.62M GBP |
| Total Debt/Equity (mrq) | 64.23 GBP |
| Current Ratio (mrq) | 2.433 |
| Book Value Per Share (mrq) | 0.193 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -39619000 GBP |
| Levered Free Cash Flow (ttm) | -26369500 GBP |
Profile of Renalytix Plc
| Country | United Kingdom |
| State | NY |
| City | New York |
| Address | 1460 Broadway |
| ZIP | 10036 |
| Phone | 646 397 3970 |
| Website | https://renalytix.com |
| Industry | Health Information Services |
| Sector(s) | Healthcare |
| Full Time Employees | 102 |
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.
Q&A For Renalytix Plc Stock
What is a current RENX.L stock price?
Renalytix Plc RENX.L stock price today per share is 32.5 GBP.
How to purchase Renalytix Plc stock?
You can buy RENX.L shares on the LSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Renalytix Plc?
The stock symbol or ticker of Renalytix Plc is RENX.L.
Which industry does the Renalytix Plc company belong to?
The Renalytix Plc industry is Health Information Services.
How many shares does Renalytix Plc have in circulation?
The max supply of Renalytix Plc shares is 1.24M.
What is Renalytix Plc Price to Earnings Ratio (PE Ratio)?
Renalytix Plc PE Ratio is now.
What was Renalytix Plc earnings per share over the trailing 12 months (TTM)?
Renalytix Plc EPS is -0.36 GBP over the trailing 12 months.
Which sector does the Renalytix Plc company belong to?
The Renalytix Plc sector is Healthcare.